These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 34195008)

  • 21. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas.
    Auriemma RS; Galdiero M; Vitale P; Granieri L; Lo Calzo F; Salzano C; Ferreri L; Pivonello C; Cariati F; Coppola G; de Angelis C; Colao A; Pivonello R
    Neuroendocrinology; 2015; 101(1):66-81. PubMed ID: 25592453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
    Pekić S; Medic Stojanoska M; Popovic V
    Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
    Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
    Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
    BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of prolactinomas.
    Ježková J; Marek J
    Expert Rev Endocrinol Metab; 2009 Mar; 4(2):135-142. PubMed ID: 30780862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cabergoline on metabolism in prolactinomas.
    Auriemma RS; Granieri L; Galdiero M; Simeoli C; Perone Y; Vitale P; Pivonello C; Negri M; Mannarino T; Giordano C; Gasperi M; Colao A; Pivonello R
    Neuroendocrinology; 2013; 98(4):299-310. PubMed ID: 24355865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new.
    Chanson P; Maiter D
    Best Pract Res Clin Endocrinol Metab; 2019 Apr; 33(2):101290. PubMed ID: 31326373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
    Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
    J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolactin in men's health and disease.
    Bolyakov A; Paduch DA
    Curr Opin Urol; 2011 Nov; 21(6):527-34. PubMed ID: 21941183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors.
    Mattogno PP; D'Alessandris QG; Chiloiro S; Bianchi A; Giampietro A; Pontecorvi A; De Marinis L; Olivi A; Anile C; Lauretti L
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34209686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels.
    Ciresi A; Amato MC; Guarnotta V; Lo Castro F; Giordano C
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):845-52. PubMed ID: 23506485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
    Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
    Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection.
    Sughrue ME; Chang EF; Tyrell JB; Kunwar S; Wilson CB; Blevins LS
    Pituitary; 2009; 12(3):158-64. PubMed ID: 18651225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
    Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
    Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS.
    Hamidi O; Van Gompel J; Gruber L; Kittah NE; Donegan D; Philbrick KA; Koeller KK; Erickson D; Natt N; Nippoldt TB; Young WF; Bancos I
    Endocr Pract; 2019 Apr; 25(4):340-352. PubMed ID: 30995432
    [No Abstract]   [Full Text] [Related]  

  • 39. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperprolactinemia and prolactinoma.
    Romijn JA
    Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.